



Dr. Daniel Brasseur,
EMEA,
7 Westferry Circus,
Canary Wharf,
London, E14 4HB
UK

cc: Myriam Chaplein

19 January 2006

**Subject: Withdrawal of Orathecin, (Rubitecan), 0.5mg and 1.25 mg Capsules
EMEA/H/C/608**

Dear Dr Brasseur:

I would like to inform the EMEA that EuroGen Pharmaceuticals Ltd. has taken the decision to withdraw the application for Marketing Authorisation of Orathecin, (Rubitecan), 0.5 mg and 1.25 mg capsules, which was intended to be used for pancreatic cancer, at this point of time.

This withdrawal is based upon our belief that we are unable at this time, to address the clinical issues relating to efficacy raised in the Rapporteur and Co-Rapporteurs' reports. All EU clinical trials are closed to patient enrolment and no compassionate use programmes are active.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for such a letter to be published on the EMEA website.

Yours sincerely,


EuroGen Pharmaceuticals Ltd.